Key facts
- Worg’s last known valuation is $247.8M (Aug 2022).
- It has raised $285.3M; the latest was Secondary Transaction - Private in Nov 2025.
- Notable investors include Puhua Capital, Hefei Hi-Tech VC, Lapam Capital, Detong Capital, Wuxi Jinkong Qiyuan Investment — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Worg
- ·The full record, as it builds
Funding rounds
No funding rounds for Worg are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Worg
Developer of a clinical-stage biopharmaceutical company intended to find treatments for allergies and diseases with high unmet medical needs and considerable commercial potential. The company offers building a pipeline for immunotherapy of allergies, autoimmune diseases, and other disorders through internal development and external partnering, enabling the acceleration of new treatment development.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Employees
- 40
- Website
- worgpharma.com/
- Ownership
- Privately Held (backing)
Worg doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Worg shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Worg in its N-PORT filings yet. We sweep new filings monthly.